Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Brian Heller (NPI 1942391784)

Field	Value
Entity Type	Individual
Organization	Brian Heller
Address	6701 Airport Blvd Bldg B
City	Mobile
State	AL
ZIP	36608
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	September 27, 2006

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider is effectively single-payer in public programs: lifetime Medicare revenue is $2.3M and there is no Medicaid billing on file, so all publicly reported claims activity and revenue derive from Medicare rather than a mixed Medicare/Medicaid practice. That makes Medicare utilization and code mix the primary lens for assessing service lines and market behavior.

Revenue is highly concentrated in a small set of drug infusion codes: the precomputed top 3 Medicare codes account for 89.3% of this provider's total Medicare revenue, indicating that a narrow group of high-cost injectable therapies dominates the practice’s billed revenue. This concentration implies the practice model is centered on outpatient administration of specialty oncology biologics rather than office-based evaluation and management visits.

Pembrolizumab (J9271) is the single largest revenue driver: J9271 accounts for $1.4M and 62.2% of the provider’s Medicare revenue and the provider ranks #76 of 1841 nationally (96th percentile). That rank and percentile indicate this provider delivers pembrolizumab at substantially higher volume than most peers, positioning them as a relatively high-volume administrator of this checkpoint inhibitor in the national Medicare population.

Nivolumab (J9299) is the second major contributor, representing $550.1K and 24.7% of Medicare revenue with a national rank of #129 of 505 providers (75th percentile). This placement reflects typical-to-above-typical participation in nivolumab administration but substantially lower scale than for pembrolizumab, reinforcing a drug-centric infusion practice with two dominant PD-1/PD-L1 agents.

The practice shows modest E/M and chemotherapy administration volume relative to its infusion business: highest non-drug E/M code 99214 produced $49.2K (2.2% of Medicare revenue) and chemotherapy administration code 96413 produced $40.7K (1.8% of Medicare revenue). Both codes rank in typical-to-high percentiles nationally, suggesting the provider performs routine clinical follow-up and direct chemotherapy services but these are secondary revenue sources compared with high-cost biologic infusions.

Several ancillary lab and infusion-related codes appear regularly but contribute only small shares of revenue, consistent with an outpatient oncology infusion center model. Examples include 36415 (blood draw) $6.4K, 85025 (CBC) $6.2K, and 96365/96367 infusion codes ($6.3K and $7.5K respectively); these items support infusion workflows but do not materially drive total Medicare revenue.

There are notable concentration and specialty signals in other drug codes as well: Q5122 (pegfilgrastim biosimilar) accounts for $56.1K (2.5% of revenue) and ranks #36 of 239 (84th percentile), and J3489 (zoledronic acid) ranks in the 96th percentile with $2.4K. These placements indicate the provider also delivers supportive oncology agents and growth-factor biosimilars at higher-than-typical volumes relative to peers.

Provider tenure is long-standing: the NPI enumerated on 2006-09-27 (~20 years ago), which supports interpretation that the current billing pattern reflects an established practice rather than a newly formed operation. That longevity, combined with concentrated high-volume biologic administrations, suggests a sustained infusion-focused oncology practice serving Medicare beneficiaries in Mobile, AL.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

55 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	33,800	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	22,920	$20	$550.1K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	660	$90	$56.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	570	$90	$49.2K
J0897	Injection, denosumab, 1 mg	2,700	$20	$48.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	460	$90	$40.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	220	$60	$12.4K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	50	$170	$8.6K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	90	$90	$7.6K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	400	$20	$7.5K

Showing 1–10 of 55

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 55 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Brian Heller — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

55 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	30	19,900	$40	$827.2K
J9299	3	10	19,060	$20	$535.1K
J0897	106	200	3,120	$20	$97.7K
Q5122	1	10	600	$90	$44.4K
96413	24	150	150	$90	$20.2K
99214	644	7,330	120	$80	$16.8K
88185	25	30	490	$20	$15.4K
99233	875	1,860	80	$90	$13.4K
99232	2,321	2,530	100	$60	$13.3K
80053	95	670	140	$10	$13.1K

Showing 1–10 of 55

Related Providers

Other providers that share a Tax Identification Number (TIN) with Brian Heller, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
William Mcevoy	AL	Hematology & Oncology Physician	$1.7M	$0
Joseph Jones	AL	Hematology & Oncology Physician	$1.6M	$0
Michael Meshad	AL	Hematology & Oncology Physician	$1.1M	$0
Jeffrey George	AL	Hematology & Oncology Physician	$1.1M	$0
Rachel Kruspe	AL	Hematology & Oncology Physician	$1M	$0
Nicole Angel	AL	Medical Oncology Physician	$985.3K	$0
Rosa Michel Ortega	AL	Hematology & Oncology Physician	$731.7K	$0
Rachael Harmon	AL	Radiation Oncology Physician	$729.3K	$0
Brittany Case	AL	Medical Oncology Physician	$727.3K	$0

Nearby Providers

Other providers in the same ZIP code as Brian Heller, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Children's Medical Group, P.A.	AL	Specialist	$0	$7.4M
Coast Diagnostics, LLC	AL	Clinical Medical Laboratory	$275.1K	$5.7M
Springhill Hospitals, Inc	AL	General Acute Care Hospital	$0	$5.3M
Pulmonary Associates Of Mobile PC	AL	Pulmonary Disease Physician	$0	$5.3M
Providence Hospital	AL	General Acute Care Hospital	$0	$4.8M
Alabama Providence Healthcare Services	AL	Internal Medicine Physician	$0	$4.7M
University Of South Alabama Health Care Authority	AL	Internal Medicine Physician	$0	$3.9M
Mobile Emergency Physicians, LLC	AL	Emergency Medicine Physician	$0	$3.3M
Imc-pediatric & Adolescent Medicine, LLC	AL	Pediatric Adolescent Medicine Physician	$0	$3.3M
Springhill Emergency Physicians, PC	AL	Emergency Medicine Physician	$0	$3.2M

Brian Heller — Billing Profile & Reimbursement Data

Sign up for Brian Heller — Billing Profile & Reimbursement Data policy alerts

Brian Heller — Billing Profile & Reimbursement Data

Sign up for Brian Heller — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References